Document:

sr-ex41_15.htm

Exhibit 4.1

 

 

Spire Alabama Inc.

 

 

 

Fifth Supplement to Master Note Purchase Agreement

 

 

 

Dated as of October 13, 2022

 

 

 

Re:$90,000,000 5.32% Series 2022A Senior Notes due October 15, 2029

          $85,000,000 5.41% Series 2022B Senior Notes due October 15, 2032

 

 

 

 

 

 

 

 

 

 

Spire Alabama Inc.

2101 6th Avenue North

Birmingham, AL 35203

 

 

Dated as of October 13, 2022

 

To the Purchasers named in

Schedule A hereto 

 

Ladies and Gentlemen:

This Fifth Supplement to Master Note Purchase Agreement (this or the “Fifth Supplement”) is between Spire Alabama Inc., an Alabama corporation (as successor to Alabama Gas Corporation, the “Company”), and the institutional investors named on Schedule A attached hereto (the “Purchasers”).

Reference is hereby made to that certain Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of June 5, 2015 (the “Master Note Purchase Agreement”), as previously supplemented by (i) that certain First Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of December 1, 2017 (the “First Supplement”); (ii) that certain Second Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of January 15, 2019 (the “Second Supplement”); (iii) that certain Third Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of December 2, 2019 (the “Third Supplement”); and (iv) that certain Fourth Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of December 15, 2020 (the “Fourth Supplement” and, together with the First Supplement, the Second Supplement, the Third Supplement, and the Master Note Purchase Agreement as amended, restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”).  All capitalized definitional terms not otherwise defined herein shall have the same meaning as specified in the Note Purchase Agreement.  Reference is further made to Section 1.2 of the Note Purchase Agreement which requires that, prior to the delivery of any Additional Notes, the Company and each Additional Purchaser shall execute and deliver a Supplement.

The Company hereby agrees with the Purchasers as follows:

1.Series 2022 Notes.  The Company has authorized the issue and sale of its (i) $90,000,000 aggregate principal amount 5.32% Series 2022A Senior Notes due October 15, 2029 (the “Series 2022A Notes”) and (ii) $85,000,000 aggregate principal amount 5.41% Series 2022B Notes due October 15, 2032 (the “Series 2022B Notes”; together with the Series 2022A Notes, collectively, the “Series 2022 Notes”).  The Series 2022A Notes and the Series 2022B Notes, 

 

 

together with the Series 2020 Notes, Series 2019A Notes, the Series 2019B Notes, the Series 2017 Notes, and the Series 2015 Notes initially issued pursuant to the Fourth Supplement, the Third Supplement, the Second Supplement, the First Supplement, and the Master Note Purchase Agreement, respectively, and each series of Additional Notes which may from time to time hereafter be issued pursuant to the provisions of Section 1.2 of the Note Purchase Agreement, are collectively referred to as the “Notes” (such term shall also include any such notes issued in substitution therefor pursuant to Section 13 of the Note Purchase Agreement).  The Series 2022 Notes shall be substantially in the forms set out in Exhibit B-1 and B-2 hereto, respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company.  

2.Subject to the terms and conditions hereof and as set forth in the Note Purchase Agreement and on the basis of the representations and warranties hereinafter set forth, the Company agrees to issue and sell to each Purchaser, and each Purchaser agrees to purchase from the Company, Series 2022 Notes of the series and in the principal amount set forth opposite such Purchaser’s name on Schedule A hereto at a price of 100% of the principal amount thereof on the closing date hereinafter mentioned.

3.The execution and delivery of this Fifth Supplement and the sale and purchase of the Series 2022 Notes to be purchased by each Purchaser shall occur at 8:00 A.M., Chicago time, at a closing on October 13, 2022 (the “Closing”) at the offices of Chapman and Cutler LLP 320 South Canal Street, Chicago, Illinois 60606.  At the Closing, the Company will deliver to each Purchaser the Series 2022 Notes to be purchased by such Purchaser in the form of a single Series 2022 Note (or such greater number of Series 2022 Notes in denominations of at least $250,000 as such Purchaser may request) dated the date of the Closing and registered in such Purchaser’s name (or in the name of such Purchaser’s nominee), against delivery by such Purchaser to the Company or its order of immediately available funds in the amount of the purchase price therefor by wire transfer of immediately available funds for the account of the Company, with wire instructions to be provided by the Company to the Purchaser at least five (5) Business Days prior to the Closing date in accordance with Section 4(d) hereof.  If, at the Closing, the Company shall fail to tender such Series 2022 Notes to any Purchaser as provided above in this Section 3, or any of the conditions specified in Section 4 shall not have been fulfilled to any Purchaser’s satisfaction, such Purchaser shall, at such Purchaser’s election, be relieved of all further obligations under this Supplement, without thereby waiving any rights such Purchaser may have by reason of such failure or such nonfulfillment.

4.The obligation of each Purchaser to purchase and pay for the Series 2022 Notes to be sold to such Purchaser at the Closing is subject to the fulfillment to such Purchaser’s satisfaction, prior to the Closing, of the conditions set forth in Section 4 of the Note Purchase Agreement (giving effect to any changes to the representations and warranties set forth in the Note Purchase Agreement effectuated by this Supplement) with respect to the Series 2022 Notes to be purchased at the Closing, and to the following additional conditions:

(a)Except as supplemented, amended or superseded by the representations and warranties set forth in Exhibit A hereto, each of the representations and warranties of the Company set forth in Section 5 of the Note Purchase Agreement shall be correct as of the 

-2-

 

date of the Closing and the Company shall have delivered to each Purchaser an Officer’s Certificate, dated the date of the Closing certifying that such condition has been fulfilled.

(b)The Company shall have consummated the sale of the entire principal amount of the Series 2022 Notes scheduled to be sold at the Closing, pursuant to this Supplement.

(c)The Master Note Purchase Agreement shall not have been amended or modified in any way since October 6, 2022 through and including the date of the Closing.

(d)At least five (5) Business Days prior to the date of the Closing, each Purchaser shall have received written instructions signed by a Responsible Officer on letterhead of the Company confirming the information specified in Section 3 including (i) the name and address of the transferee bank, (ii) such transferee bank’s ABA number, (iii) the account name and number into which the purchase price for the relevant series of Notes is to be deposited and (iv) the contact information of a representative at both the transferee bank and the Company who can verbally confirm such wire instructions.  Each Purchaser has the right, but not the obligation, upon written notice (which may be by email) to the Company, to elect to deliver a micro deposit (less than $51.00) to the account identified in the written instructions no later than two (2) Business Days prior to Closing.  If a Purchaser delivers a micro deposit, a Responsible Officer must verbally verify the receipt and amount of the micro deposit to such Purchaser on a telephone call initiated by such Purchaser prior to Closing.  The Company shall not be obligated to return the amount of the micro deposit, nor will the amount of the micro deposit be netted against the Purchaser’s purchase price of the Notes.

5.(a)   As provided on each Series 2022 Note, (i) the entire unpaid principal balance of each Series 2022A Note shall be due and payable on October 15, 2029 and (ii) the entire unpaid principal balance of each Series 2022B Note shall be due and payable on October 15, 2032. 

(b)   Optional Prepayments without Make-Whole Amount.  On any date prior to July 15, 2029 in the case of the Series 2022A Notes, and on any date prior to July 15, 2032 in the case of the Series 2022B Notes, the Company may, at its option, in accordance with, and upon notice as provided in, Section 8.2 of the Master Note Purchase Agreement, prepay at any time all, or from time to time any part of, such series of the Series 2022 Notes (but if in part then in a minimum aggregate principal amount of $100,000), at 100% of the principal amount so prepaid, together with interest accrued thereon to the date of such prepayment, plus the Make-Whole Amount determined for the prepayment date with respect to such principal amount.  On any date on or after July 15, 2029 in the case of the Series 2022A Notes, and on any date on or after July 15, 2032 in the case of the Series 2022B Notes, the Company may, at its option, upon notice as provided Section 8.2 of the Master Note Purchase Agreement, prepay at any time all of such series of the Series 2022 Notes, at 100% of the principal amount so prepaid, together with interest accrued thereon to the date of such prepayment, but without payment of the Make-Whole Amount.

6.The term “Make-Whole Amount” means, with respect to any Series 2022 Note, an amount equal to the excess, if any, of the Discounted Value of the Remaining Scheduled Payments 

-3-

 

with respect to the Called Principal of such Series 2022 Note over the amount of such Called Principal, provided that the Make-Whole Amount may in no event be less than zero.  For the purposes of determining the Make-Whole Amount, the following terms have the following meanings:

“Called Principal” means, with respect to any Series 2022 Note, the principal of such Series 2022 Note that is to be prepaid pursuant to Section 8.2 of the Note Purchase Agreement or has become or is declared to be immediately due and payable pursuant to Section 12.1 of the Note Purchase Agreement, as the context requires.

“Discounted Value” means, with respect to the Called Principal of any Series 2022 Note, the amount obtained by discounting all Remaining Scheduled Payments with respect to such Called Principal from their respective scheduled due dates to the Settlement Date with respect to such Called Principal, in accordance with accepted financial practice and at a discount factor (applied on the same periodic basis as that on which interest on the Series 2022 Notes is payable) equal to the Reinvestment Yield with respect to such Called Principal.

“Reinvestment Yield” means, with respect to the Called Principal of any Series 2022 Note, the sum of (a) 0.50% (50 basis points) plus (b) the yield to maturity implied by the “Ask Yield(s)” reported as of 10:00 A.M. (New York City time) on the second Business Day preceding the Settlement Date with respect to such Called Principal, on the display designated as “Page PX1” (or such other display as may replace Page PX1) on Bloomberg Financial Markets for the most recently issued actively traded on-the-run U.S. Treasury securities (“Reported”) having a maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date.  If there are no such U.S. Treasury securities Reported having a maturity equal to such Remaining Average Life, then such implied yield to maturity will be determined by (i) converting U.S. Treasury bill quotations to bond equivalent yields in accordance with accepted financial practice and (ii) interpolating linearly between the “Ask Yields” Reported for the applicable most recently issued actively traded on-the-run U.S. Treasury securities with the maturities (1) closest to and greater than such Remaining Average Life and (2) closest to and less than such Remaining Average Life.  The Reinvestment Yield shall be rounded to the number of decimal places as appears in the interest rate of such Series 2022 Note.  

If such yields are not Reported or the yields Reported as of such time are not ascertainable (including by way of interpolation), then “Reinvestment Yield” means, with respect to the Called Principal of any Series 2022 Note, the sum of (x) 0.50% (50 basis points) plus (y) the yield to maturity implied by the U.S. Treasury constant maturity yields reported, for the latest day for which such yields have been so reported as of the second Business Day preceding the Settlement Date with respect to such Called Principal, in Federal Reserve Statistical Release H.15 (or any comparable successor publication) for the U.S. Treasury constant maturity having a term equal to the Remaining Average Life of such Called Principal as of such Settlement Date.  If there is no such U.S. Treasury constant maturity having a term equal to such Remaining Average Life, such implied yield to maturity will be determined by interpolating linearly between (1) the U.S. Treasury constant maturity so reported with the term closest to and greater than such Remaining Average Life and (2) the U.S. Treasury constant maturity so reported with the term closest to and 

-4-

 

less than such Remaining Average Life.  The Reinvestment Yield shall be rounded to the number of decimal places as appears in the interest rate of such Series 2022 Note.

“Remaining Average Life” means, with respect to any Called Principal, the number of years obtained by dividing (i) such Called Principal into (ii) the sum of the products obtained by multiplying (a) the principal component of each Remaining Scheduled Payment with respect to such Called Principal by (b) the number of years, computed on the basis of a 360-day year comprised of twelve 30-day months and calculated to two decimal places, that will elapse between the Settlement Date with respect to such Called Principal and the scheduled due date of such Remaining Scheduled Payment.

“Remaining Scheduled Payments” means, with respect to the Called Principal of any Series 2022 Note, all payments of such Called Principal and interest thereon that would be due after the Settlement Date with respect to such Called Principal if no payment of such Called Principal were made prior to its scheduled due date, provided that if such Settlement Date is not a date on which interest payments are due to be made under the Series 2022 Notes, then the amount of the next succeeding scheduled interest payment will be reduced by the amount of interest accrued to such Settlement Date and required to be paid on such Settlement Date pursuant to Section 8.2 of the Note Purchase Agreement or Section 12.1 of the Note Purchase Agreement.

“Settlement Date” means, with respect to the Called Principal of any Series 2022 Note, the date on which such Called Principal is to be prepaid pursuant to Section 8.2 of the Note Purchase Agreement or has become or is declared to be immediately due and payable pursuant to Section 12.1 of the Note Purchase Agreement, as the context requires.

7.For the purpose of the Note Purchase Agreement and this Supplement, the terms below have the following meanings with respect to any holder of a Series 2022 Note:

“Parent” shall mean Spire Inc., a Missouri corporation.

“Wells Facility” means the Amended and Restated Loan Agreement, dated as of July 22, 2022, among the Parent, the Company, Spire Missouri Inc., a Missouri corporation, the lenders from time to time party thereto as Banks, and Wells Fargo Bank, National Association, as administrative agent for such Banks, or any successor administrative agent, as the same may be amended, renewed, restated, replaced or otherwise modified from time to time.

8.Each Purchaser represents and warrants that the representations and warranties set forth in Section 6 of the Note Purchase Agreement are true and correct on the date of the Closing with respect to the purchase of the Series 2022 Notes by such Purchaser.

9.Except as otherwise required by applicable law, the Company agrees that it will not withhold from any applicable payment to be made to a holder of a Note that is not a United States Person any tax so long as such holder shall have delivered to the Company (in such number of copies as shall be requested) on or about the date on which such holder becomes a holder under this Supplement (and from time to time thereafter upon the reasonable request of the Company), executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, as well as the 

-5-

 

applicable U.S. Tax Compliance Certificate substantially in the form attached as Exhibit C, in both cases correctly completed and executed.

10.Notwithstanding Section 17.2(c) of the Master Note Purchase Agreement, any consent made pursuant to Section 17.2 of the Master Note Purchase Agreement by the holder of any Note that has transferred or has agreed to transfer such Note to the (i) Company, (ii) any Subsidiary or any Affiliate of the Company, or (iii) any other Person in connection with, or in anticipation of, such other Person acquiring, making a tender offer for or merging with the Company and/or any of its Affiliates, in each case in connection with such written consent, such transfer shall be void and of no force or effect except solely as to such holder, and any amendments effected or waivers granted or to be effected or granted that would not have been or would not be so effected or granted but for such consent (and the consents of all other holders of Notes that were acquired under the same or similar conditions) shall be void and of no force or effect except solely as to such transferring holder.

11.Subject to the terms of this Supplement, the Company and each Purchaser agree to be bound by and comply with the terms and provisions of the Note Purchase Agreement as fully and completely as if such Purchaser were an original signatory to the Note Purchase Agreement.

* * * * *

 

 

-6-

 

 

The execution hereof shall constitute a contract between the Company and the Purchasers for the uses and purposes hereinabove set forth, and this agreement may be executed in any number of counterparts, each executed counterpart constituting an original but all together only one agreement.

 

Spire Alabama Inc.

 

 

 

		
	
By
	
/s/ Adam W. Woodard

	
 
	
Name: Adam W. Woodard

	
 
	
Title: Vice President, Chief Financial Officer and Treasurer

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

The Northwestern Mutual Life Insurance Company

By: Northwestern Mutual Investment Management Company, LLC, its investment adviser

 

 

 

		
	
By:
	
/s/ Timothy S. Collins

	
 
	
Name: Timothy S. Collins

	
 
	
Title: Managing Director

 

 

 

The Northwestern Mutual Life Insurance Company for its Group Annuity Separate Account

By: Northwestern Mutual Investment Management Company, LLC, its investment adviser

 

 

 

		
	
By:
	
/s/ Timothy S. Collins

	
 
	
Name: Timothy S. Collins

	
 
	
Title: Managing Director

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

State Farm Life Insurance Company

 

 

		
	
By:
	
/s/ Rebekah L. Holt

	
 
	
Name: Rebekah L. Holt

	
 
	
Title: Investment Professional

 

		
	
By:
	
/s/ Jeffrey Attwood

	
 
	
Name: Jeffrey Attwood

	
 
	
Title: Investment Professional

 

 

 

State Farm Life and Accident Assurance Company

 

 

		
	
By:
	
/s/ Rebekah L. Holt

	
 
	
Name: Rebekah L. Holt

	
 
	
Title: Investment Professional

 

		
	
By:
	
/s/ Jeffrey Attwood

	
 
	
Name: Jeffrey Attwood

	
 
	
Title: Investment Professional

 

 

 

State Farm Insurance Companies Employee Retirement Trust

 

 

		
	
By:
	
/s/ Rebekah L. Holt

	
 
	
Name: Rebekah L. Holt

	
 
	
Title: Investment Professional

 

		
	
By:
	
/s/ Jeffrey Attwood

	
 
	
Name: Jeffrey Attwood

	
 
	
Title: Investment Professional

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

Missouri Reinsurance, Inc.

By: MetLife Investment Management, LLC, its Investment Manager

 

 

 

		
	
By:
	
/s/ Fred Sporer

	
 
	
Name: Frederic Sporer

	
 
	
Title: Authorized Signatory

 

 

 

Horizon Blue Cross Blue Shield of New Jersey

By: MetLife Investment Management, LLC, its Investment Manager

 

 

 

		
	
By:
	
/s/ Fred Sporer

	
 
	
Name: Frederic Sporer

	
 
	
Title: Authorized Signatory

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

Equitable Financial Life Insurance Company

 

 

 

		
	
By:
	
/s/ Amy Judd

	
 
	
Name: Amy Judd

	
 
	
Title: Investment Officer

 

 

 

Corporate Solutions Life Reinsurance Company

 

 

 

		
	
By:
	
/s/ Amy Judd

	
 
	
Name: Amy Judd

	
 
	
Title: Investment Officer

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

CMFG Life Insurance Company

By: MEMBERS Capital Advisors, Inc.

      acting as Investment Adviser

 

 

 

		
	
By:
	
/s/ Stan J. Van Aartsen

	
 
	
Name: Stan J. Van Aartsen

	
 
	
Title: Managing Director, Investments

 

 

 

Union Security Insurance Company

By: MEMBERS Capital Advisors, Inc.

      acting as Investment Adviser

 

 

 

		
	
By:
	
/s/ Stan J. Van Aartsen

	
 
	
Name: Stan J. Van Aartsen

	
 
	
Title: Managing Director, Investments

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

Modern Woodmen of America

 

 

 

		
	
By:
	
/s/ Aaron R. Birkland

	
 
	
Name: Aaron R. Birkland

	
 
	
Title: Portfolio Manager, Private Placements

 

 

 

		
	
By:
	
/s/ Brett M. Van

	
 
	
Name: Brett M. Van

	
 
	
Title: Chief Investment Officer & Treasurer

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

Protective Property & Casualty Insurance Company

 

 

 

		
	
By:
	
/s/ John Roesle

	
 
	
Name: John Roesle

	
 
	
Title: VP, Investments

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

The Guardian Life Insurance Company of America

By: Park Avenue Institutional Advisers LLC, its Investment Manager

 

 

 

		
	
By:
	
/s/ Amy Carroll

	
 
	
Name: Amy Carroll

	
 
	
Title: Authorized Signatory

 

 

 

 

 

 

 

 

This Fifth Supplement is hereby

accepted and agreed to as

of the date hereof.

 

Woodmen of the World Life Insurance Society

 

 

 

		
	
By:
	
/s/ Shawn Bengtson

	
 
	
Name: Shawn Bengtson

	
 
	
Title: Executive Vice President & Chief Risk Officer

 

 

 

		
	
By:
	
/s/ Dean R. Holdsworth

	
 
	
Name: Dean R. Holdsworth

	
 
	
Title: Director – Mortgage and Real Estate Investment

 

 

 

 

 

 

 

 

Information Relating to Purchasers

[Contact information and wire transfer instructions included on Schedule A are omitted from this SEC filing.]

			
	
Purchaser
	
Principal Amount

	
Series 2022A
	
Series 2022B

	
The Northwestern Mutual Life Insurance Company
	
$40,000,000
	
$24,155,000

	
The Northwestern Mutual Life Insurance Company 

for its Group Annuity Separate Account
	
$0
	
$845,000

	
State Farm Life Insurance Company
	
$24,000,000
	
$13,500,000

	
State Farm Life and Accident Assurance Company
	
$1,000,000
	
$1,000,000

	
State Farm Insurance Companies Employee Retirement Trust
	
$0
	
$500,000

	
Missouri Reinsurance, Inc.
	
$2,500,000
	
$20,000,000

	
Horizon Blue Cross Blue Shield of New Jersey
	
$2,500,000
	
$0

	
Equitable Financial Life Insurance Company
	
$5,000,000
	
$0

	
Equitable Financial Life Insurance Company
	
$5,000,000
	
$0

	
Corporate Solutions Life Reinsurance Company
	
$1,000,000
	
$0

	
Corporate Solutions Life Reinsurance Company
	
$4,000,000
	
$0

	
Corporate Solutions Life Reinsurance Company
	
$4,000,000
	
$0

	
Corporate Solutions Life Reinsurance Company
	
$1,000,000
	
$0

	
TURNKEYS & CO as nominee for CMFG Life Insurance Company
	
$0
	
$2,000,000

	
TURNKEYS & CO as nominee for CMFG Life Insurance Company
	
$0
	
$3,000,000

	
WINDYRIVERS & CO as nominee for Union Security Insurance Company
	
$0
	
$2,000,000

	
Modern Woodman of America
	
$0
	
$6,000,000

	
Protective Property & Casualty Insurance Company
	
$0
	
$5,000,000

	
The Guardian Life Insurance Company of America
	
$0
	
$4,000,000

	
Woodmen of the World Life Insurance Society
	
$0
	
$3,000,000

 

 

 

 

Schedule A

(to Supplement)

 

 

Exhibit A

Supplemental Representations

The Company represents and warrants to each Purchaser that except as hereinafter set forth in this Exhibit A, each of the representations and warranties set forth in Section 5 of the Note Purchase Agreement is true and correct in all respects as of the date of the Closing with respect to the Series 2022 Notes with the same force and effect as if each reference to “Series 2015 Notes” set forth therein was modified to refer to the “Series 2022 Notes” and each reference to “this Agreement” therein was modified to refer to the Note Purchase Agreement as supplemented by the Fifth Supplement.  The Section references hereinafter set forth correspond to the similar sections of the Note Purchase Agreement which are supplemented hereby:

Section 5.3.Disclosure.  The Company has delivered to each Purchaser a copy of its financial statements listed in Schedule 5.5.  The Note Purchase Agreement, the Fifth Supplement, and the documents, certificates or other writings delivered to the Purchasers by or on behalf of the Company in connection with the transactions contemplated by the Note Purchase Agreement and the Fifth Supplement and identified in Schedule 5.3, and the financial statements listed in Schedule 5.5 (the Note Purchase Agreement, the Fifth Supplement, and such documents, certificates or other writings and such financial statements delivered to each Purchaser prior to October 6, 2022 being referred to, collectively, as the “Disclosure Documents”), taken as a whole, do not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made; provided that, with respect to projections, budgets and other estimates, the Company represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time.  Except as disclosed in the Disclosure Documents, since September 30, 2021, there has been no change in the financial condition, operations, business or properties of the Company or any of its Subsidiaries except changes that individually or in the aggregate would not reasonably be expected to have a Material Adverse Effect.

Section 5.4.Organization and Ownership of Shares of Subsidiaries.  Schedule 5.4 to the Fifth Supplement is (except as noted therein), as of the date of the Closing a complete and correct list of the Company’s Subsidiaries, showing, as to each Subsidiary, the correct name thereof, the jurisdiction of its organization, and the percentage of shares of each class of its Capital Stock outstanding owned by the Company and each other Subsidiary.

Section 5.13.Private Offering by the Company.  Neither the Company nor anyone acting on its behalf has offered the Series 2022 Notes or any similar Securities for sale to, or solicited any offer to buy any of the same from, or otherwise approached or negotiated in respect thereof with, any Person other than not more than nineteen (19) Institutional Investors (including the Purchasers), each of which has been offered the Series 2022 Notes at a private sale for investment.  Neither the Company nor anyone acting on its behalf has taken, or will take, any action that would subject the issuance or sale of the Series 2022 Notes to the registration requirements of Section 5 of the Securities Act or to the registration requirements of any securities or blue sky laws of any applicable jurisdiction.

Exhibit A

(to Supplement)

 

Section 5.14.Use of Proceeds; Margin Regulations.  The Company will apply the proceeds of the sale of the Series 2022 Notes to refinance existing debt and for general corporate purposes.  No part of the proceeds from the sale of the Series 2022 Notes under the Fifth Supplement will be used, directly or indirectly, for the purpose of buying or carrying any margin stock within the meaning of Regulation U of the Board of Governors of the Federal Reserve System (12 CFR 221), or for the purpose of buying or carrying or trading in any Securities under such circumstances as to involve the Company in a violation of Regulation X of said Board (12 CFR 224) or to involve any broker or dealer in a violation of Regulation T of said Board (12 CFR 220).  Margin stock does not constitute more than 15% of the value of the consolidated assets of the Company and its Subsidiaries and the Company does not have any present intention that margin stock will constitute more than 15% of the value of such assets.  As used in this Section 5.14, the terms “margin stock” and “purpose of buying or carrying” shall have the meanings assigned to them in said Regulation U.

Section 5.15.Existing Indebtedness.  Except as described therein, Schedule 5.15 to the Fifth Supplement sets forth a complete and correct list of all outstanding Indebtedness of the Company and its Subsidiaries as of June 30, 2022 (including a description of the obligors and obligees, principal amount outstanding and collateral therefor, if any, and Guaranty thereof, if any), since which date there has been no Material change in the amounts, interest rates, sinking funds, installment payments or maturities of the Indebtedness of the Company or its Subsidiaries (other than as permitted hereunder).  Neither the Company nor any Subsidiary is in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of the Company or such Subsidiary and no event or condition exists with respect to any Indebtedness of the Company or any Subsidiary the outstanding principal amount of which exceeds $10,000,000 that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Indebtedness to become due and payable before its stated maturity or before its regularly scheduled dates of payment.

 

 

A-2

 

 

[Form of Series 2022A Note]

Spire Alabama Inc.

5.32% Series 2022A Senior Note, due October 15, 2029

 

		
	
No. 2022A-[__]
	
[Date]

	
$[_______]
	
PPN 84858# AF0

 

For Value Received, the undersigned, Spire Alabama Inc. (herein called the “Company”), a corporation organized and existing under the laws of the State of Alabama, hereby promises to pay to [____________], or its registered assigns, the principal sum of [_____________________] Dollars (or so much thereof as shall not have been prepaid) on October 15, 2029, with interest (computed on the basis of a 360-day year of twelve 30‐day months) (a) on the unpaid balance hereof at the 5.32% per annum from the date hereof, payable semi-annually, on the 15th day of April and October  in each year, with the first interest payment hereunder on April 15, 2023 and thereafter on the April 15th or October 15th next succeeding the date hereof, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law, on any overdue payment (including any overdue prepayment) of principal, any overdue payment of interest and any overdue payment of any Make‐Whole Amount, payable semi‐annually as aforesaid (or, at the option of the registered holder hereof, on demand), at a rate per annum from time to time equal to the greater of (i) 7.32% and (ii) 2.0% over the rate of interest publicly announced by Chase Bank, N.A. from time to time in New York, New York as its “base” or “prime” rate.

Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at Regions Bank or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreement referred to below.

This Note is one of a series of Senior Notes (herein called the “Notes”) issued pursuant to a Fifth Supplement dated as of October 13, 2022 to the Master Note Purchase Agreement, dated as of June 5, 2015 (as from time to time amended, restated and supplemented, the “Note Purchase Agreement”), between the Company and the respective Purchasers named therein and is entitled to the benefits thereof.  Each holder of this Note will be deemed, by its acceptance hereof, to have (i) agreed to the provisions of the Note Purchase Agreement, including, without limitation, the confidentiality provisions set forth in Section 20 of the Note Purchase Agreement and (ii) made the representations set forth in Section 6.1 and Section 6.2 of the Note Purchase Agreement.  Unless otherwise indicated, capitalized terms used in this Note shall have the respective meanings ascribed to such terms in the Note Purchase Agreement.

This Note is a registered Note and, as provided in the Note Purchase Agreement, upon surrender of this Note for registration of transfer, accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, 

Exhibit B-1

(to Supplement)

 

a new Note for a like principal amount will be issued to, and registered in the name of, the transferee.  Prior to due presentment for registration of transfer, the Company may treat the Person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Company will not be affected by any notice to the contrary.

This Note is subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise.  

If an Event of Default occurs and is continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement.

[Signature Page Follows]

 

B1-2

 

 

This Note shall be construed and enforced in accordance with, and the rights of the Company and the holder of this Note shall be governed by, the law of the State of New York excluding choice-of-law principles of the law of such State that would permit the application of the laws of a jurisdiction other than such State.

 

Spire Alabama Inc.

 

 

		
	
By
	
 

	
 
	
Name:

	
 
	
Title:

 

 

 

B1-3

 

 

[Form of Series 2022B Note]

Spire Alabama Inc.

5.41% Series 2022B Senior Note, due October 15, 2032

 

		
	
No. 2022B-[__]
	
[Date]

	
$[_______]
	
PPN 84858# AG8

 

For Value Received, the undersigned, Spire Alabama Inc. (herein called the “Company”), a corporation organized and existing under the laws of the State of Alabama, hereby promises to pay to [____________], or its registered assigns, the principal sum of [_____________________] Dollars (or so much thereof as shall not have been prepaid) on October 15, 2032, with interest (computed on the basis of a 360-day year of twelve 30‐day months) (a) on the unpaid balance hereof at the 5.41% per annum from the date hereof, payable semi-annually, on the 15th day of April and October  in each year, with the first interest payment hereunder on April 15, 2023 and thereafter on the April 15th or October 15th next succeeding the date hereof, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law, on any overdue payment (including any overdue prepayment) of principal, any overdue payment of interest and any overdue payment of any Make‐Whole Amount, payable semi‐annually as aforesaid (or, at the option of the registered holder hereof, on demand), at a rate per annum from time to time equal to the greater of (i) 7.41% and (ii) 2.0% over the rate of interest publicly announced by Chase Bank, N.A. from time to time in New York, New York as its “base” or “prime” rate.

Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at Regions Bank or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreement referred to below.

This Note is one of a series of Senior Notes (herein called the “Notes”) issued pursuant to a Fifth Supplement dated as of October 13, 2022 to the Master Note Purchase Agreement, dated as of June 5, 2015 (as from time to time amended, restated and supplemented, the “Note Purchase Agreement”), between the Company and the respective Purchasers named therein and is entitled to the benefits thereof.  Each holder of this Note will be deemed, by its acceptance hereof, to have (i) agreed to the provisions of the Note Purchase Agreement, including, without limitation, the confidentiality provisions set forth in Section 20 of the Note Purchase Agreement and (ii) made the representations set forth in Section 6.1 and Section 6.2 of the Note Purchase Agreement.  Unless otherwise indicated, capitalized terms used in this Note shall have the respective meanings ascribed to such terms in the Note Purchase Agreement.

This Note is a registered Note and, as provided in the Note Purchase Agreement, upon surrender of this Note for registration of transfer, accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, 

Exhibit B-2

(to Supplement)

 

a new Note for a like principal amount will be issued to, and registered in the name of, the transferee.  Prior to due presentment for registration of transfer, the Company may treat the Person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Company will not be affected by any notice to the contrary.

This Note is subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise.  

If an Event of Default occurs and is continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement.

[Signature Page Follows]

 

B2-2

 

 

This Note shall be construed and enforced in accordance with, and the rights of the Company and the holder of this Note shall be governed by, the law of the State of New York excluding choice-of-law principles of the law of such State that would permit the application of the laws of a jurisdiction other than such State.

 

Spire Alabama Inc.

 

 

		
	
By
	
 

	
 
	
Name:

	
 
	
Title:

 

 

 

 

B2-3

 

 

[FORM OF] 

U.S. TAX COMPLIANCE CERTIFICATE

 

Reference is hereby made to that certain Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of June 5, 2015 (the “Master Note Purchase Agreement”), as supplemented by (i) that certain First Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of December 1, 2017 (the “First Supplement”), (ii) that certain Second Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of January 15, 2019 (the “Second Supplement”), (iii) that certain Third Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of December 2, 2019 (the “Third Supplement”), (iv) that certain Fourth Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of December 15, 2020 (the “Fourth Supplement”), and (v) that certain Fifth Supplement to Master Note Purchase Agreement between the Company and the purchasers listed on the Schedule A thereto and dated as of October 13, 2022 (the “Fifth Supplement”; and, together with the First Supplement, the Second Supplement, the Third Supplement, the Fourth Supplement, and the Master Note Purchase Agreement and as amended, restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”).  Unless otherwise defined herein, capitalized terms defined in the Note Purchase Agreement and used herein have the meanings given to them in the Note Purchase Agreement.

Pursuant to the provisions of Section 9 of the Fifth Supplement, the undersigned hereby certifies that:

	
 
	
(i)
	
it is the sole record and beneficial owner of the Notes in respect of which it is providing this certificate;

	
 
	
(ii)
	
it is not a bank within the meaning of Section 881(c)(3)(A) of the Code;

	
 
	
(iii)
	
it is not a ten percent shareholder of the Company within the meaning of Section 871(h)(3)(B) of the Code; and 

	
 
	
(iv)
	
it is not a controlled foreign corporation related to the Company as described in Section 881(c)(3)(C) of the Code.

The undersigned has furnished the Company with a certificate of its non-U.S. Person status on IRS W-8BEN-E.  

 

		
	
[Noteholder]

	
By:

	
 
	
Name:  

	
 
	
Title:  

Date: ________ __, ____

 

Exhibit C

(to Supplement)

 

 

Schedule 5.3

Disclosure Materials

 

None.

 

Schedule 5.3
(to Supplement)

 

 

Schedule 5.4

Organization and Ownership of Shares of Subsidiaries

 

None.

Schedule 5.4
(to Supplement)

 

 

Schedule 5.5

Financial Statements

 

	
 
	
•
	
Form 10-Q filed by Spire Inc., Spire Missouri Inc. and Spire Alabama Inc. for the quarterly periods ended December 31, 2021, March 31, 2022, and June 30, 2022: http://investors.spireenergy.com/filings-and-reports/sec-filings 

 

	
 
	
•
	
Form 10-K filed by Spire Inc., Spire Missouri Inc. and Spire Alabama Inc. for the year ended September 30, 2021: 

http://investors.spireenergy.com/filings-and-reports/sec-filings

 

	
 
	
•
	
Form 10-K filed by Spire Inc., Spire Missouri Inc. and Spire Alabama Inc. for the year ended September 30, 2020: 
http://investors.spireenergy.com/filings-and-reports/sec-filings  

 

	
 
	
•
	
Form 10-K filed by Spire Inc., Spire Missouri Inc. and Spire Alabama Inc. for the year ended September 30, 2019: 
http://investors.spireenergy.com/filings-and-reports/sec-filings 

 

 

Schedule 5.5
(to Supplement)

 

 

Schedule 5.15

Existing Indebtedness

 

				
	
Issue Date
	
Maturity
	
Par (0,000)
	
Coupon

	
9/15/2015
	
9/15/2025
	
$35,000
	
3.21%

	
12/2/2019
	
12/1/2029
	
$100,000
	
2.88%

	
12/15/2020
	
12/15/2030
	
$150,000
	
2.04%

	
1/15/2007
	
1/15/2037
	
$45,000
	
5.90%

	
12/1/2015
	
12/1/2045
	
$80,000
	
4.31%

	
1/12/2018
	
1/15/2048
	
$45,000
	
3.92%

	
1/15/2019
	
1/15/2049
	
$90,000
	
4.64%

	
12/1/2017
	
1/15/2058
	
$30,000
	
4.02%

	
 
	
 
	
$575,000
	
3.53%

 

 

 

Short-term borrowings from Spire Inc. as of 6/30/22 totaling $196,340,000.

 

 

 

Schedule 5.15
(to Supplement)Exhibit
10.1

 

Execution
Version

 

VOTING
AND SUPPORT AGREEMENT 

 

THIS
VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of October 18, 2022, by and among
Advaxis, Inc., a Delaware corporation (“Parent”); and Israel Biotech Fund I, L.P., a Cayman Islands Exempted Limited
Partnership (“Stockholder”).

 

WHEREAS,
concurrently with the execution and delivery of this Agreement, Parent, Doe Merger Sub, Inc., a Delaware corporation and a wholly owned
Subsidiary of Parent (“Merger Sub”), and Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
are entering into an Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), providing,
among other things, for the merger of Merger Sub with and into the Company, with the Company being the surviving corporation (the “Merger”);
and

 

WHEREAS,
as a condition of and inducement to Parent’s willingness to enter into the Merger Agreement, Parent and Merger Sub have required
that Stockholder enter into this Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth in this
Agreement and in the Merger Agreement, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.
Certain Definitions. For the purposes of this Agreement, capitalized terms used but not otherwise defined in this Agreement have
the meanings ascribed to them in the Merger Agreement, and other capitalized terms used herein have the respective meanings ascribed
to them in this Section 1.

 

“Additional
Owned Shares” means all shares of Company Common Stock and any other equity securities of the Company which are beneficially
owned by Stockholder and are acquired after the date hereof and prior to the Expiration Date.

 

“Affiliate”
has the meaning set forth in the Merger Agreement; provided, however, that the Company shall not be deemed to be an Affiliate
of Stockholder.

 

“beneficial
ownership” (and related terms such as “beneficially owned” or “beneficial owner”) has the meaning set
forth in Rule 13d-3 under the Exchange Act, and a Person’s beneficial ownership of securities shall be calculated in accordance
with the provisions of such rule (in each case, irrespective of whether or not such rule is actually applicable in such circumstance).

 

“Covered
Shares” means the Owned Shares and Additional Owned Shares.

 

“Expiration
Date” has the meaning set forth in Section 6.

 

“knowledge
of Stockholder” means, for any Stockholder that is an individual, the actual knowledge of such Stockholder and, for any Stockholder
that is not an individual, the actual knowledge of any officer of Stockholder.

 

    	1

    	 

    

 

“Liens”
has the meaning set forth in Section 5(a).

 

“Owned
Shares” means all shares of Company Common Stock and any other equity securities of the Company which are beneficially owned
by Stockholder as of the date hereof, as set forth on Schedule I.

 

“Permitted
Transfer” has the meaning set forth in Section 3(a).

 

“Representatives”
means, with respect to a Person, all of the officers, directors, employees, consultants, legal representatives, agents, advisors, auditors,
investment bankers, and other advisors, agents or representatives of such Person.

 

“Transfer”
means, with respect to a security, the transfer, pledge, hypothecation, encumbrance, assignment or other disposition (whether by sale,
merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise, and including the creation of any Liens) of such
security or the beneficial ownership thereof, the offer to make such a transfer or other disposition, and each option, agreement, arrangement
or understanding, whether or not in writing, to effect any of the foregoing. As a verb, “Transfer” has a correlative
meaning.

 

2.
Agreement to Vote. Prior to the Expiration Date, at the Company Stockholders Meeting, however called, or at any adjournment or
postponement thereof, or in any other circumstance in which the vote, consent or other approval of the stockholders of the Company is
sought, Stockholder irrevocably and unconditionally agrees that it shall, and shall cause any other holder of record of Stockholder’s
Covered Shares to, (a) appear at each such meeting or otherwise cause all Covered Shares to be counted as present thereat for purposes
of calculating a quorum and (b) vote (or cause to be voted), or execute and deliver a written consent (or cause a written consent to
be executed and delivered) covering, all Covered Shares:

 

(i)
in favor of the adoption of the Merger Agreement and the approval of the Merger and the other transactions contemplated by the Merger
Agreement, and the execution and delivery by the Company of the Merger Agreement and the approval of the terms thereof and each of the
other actions contemplated by the Merger Agreement and this Agreement;

 

(ii)
in favor of any adjournment or postponement recommended by the Company with respect to the Company Stockholders Meeting to the extent
permitted or required pursuant to Section 5.5(a) of the Merger Agreement;

 

(iii)
against any Company Acquisition Proposal, except as expressly permitted by Section 5.2 of the Merger Agreement;

 

(iv)
against any merger agreement or merger (other than the Merger Agreement and the Merger), consolidation, combination, sale of substantial
assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company, in each case except as expressly
permitted by Section 5.2 of the Merger Agreement; and

 

    	2

    	 

    

 

(v)
against any proposal, action or agreement that would reasonably be expected to (A) materially delay or postpone, prevent or otherwise
impair the Merger or the other transactions contemplated by the Merger Agreement, (B) result in a breach in any respect of any covenant,
representation, warranty or any other obligation or agreement of the Company under the Merger Agreement, (C) result in a breach in any
respect of any covenant, representation, warranty or any other obligation or agreement of Stockholder under this Agreement, (D) result
in any of the conditions set forth in Section 6 of the Merger Agreement not being fulfilled or (E) except as expressly contemplated by
the Merger Agreement, change in any manner the dividend policy or capitalization of, including the voting rights of any class of capital
stock of, the Company. Stockholder shall not commit or agree to take any action inconsistent with the foregoing.

 

3.
No Disposition or Solicitation.

 

(a)
No Disposition or Adverse Act. Stockholder hereby covenants and agrees that, except as contemplated by this Agreement and the
Merger Agreement, prior to the Expiration Date, Stockholder shall not (i) offer to Transfer, Transfer or consent to any Transfer of any
or all of the Covered Shares or any interest therein without the prior written consent of Parent, (ii) enter into any contract, option
or other agreement or understanding with respect to any Transfer of any or all Covered Shares or any interest therein, (iii) grant any
proxy, power-of-attorney or other authorization or consent in or with respect to any or all of the Covered Shares (other than a proxy
card or broker instructions directing that the Covered Shares be voted in accordance with Section 2), (iv) deposit any or all of the
Covered Shares into a voting trust or enter into a voting agreement or arrangement with respect to any or all of the Covered Shares or
(v) take any other action that would make any representation or warranty of Stockholder contained herein untrue or incorrect or in any
way restrict, limit or interfere with the performance of Stockholder’s obligations hereunder or the transactions contemplated hereby
or by the Merger Agreement. Notwithstanding the foregoing, a Stockholder may Transfer Covered Shares (i) to effect a “cashless
exercise” to pay the exercise price of Company Options or to satisfy such Stockholder’s Tax withholding obligations in connection
with such exercise, as permitted pursuant to the terms of any of the Company Equity Awards, (ii) to effect a “net settlement”
of Company RSUs to satisfy such Stockholder’s Tax withholding obligations upon the settlement of a Company RSU, as permitted pursuant
to the terms of any of the Company Equity Awards, (iii), in the case of a Stockholder that is not an individual, to an Affiliate of such
Stockholder and (iv), in the case of a Stockholder that is an individual, (A) to any member of such Stockholder’s immediate family,
(B) to a trust for the sole benefit of such Stockholder or any member of such Stockholder’s immediate family (i.e., spouse, lineal
descendant or antecedent, brother or sister, adopted child or grandchild or the spouse of any child, adopted child, grandchild or adopted
grandchild), (C) upon the death of such Stockholder, and (D) by will, divorce decree, intestacy or other similar law; provided that
any such Transfer referenced in clauses (iii) - (iv) shall be permitted only if the applicable transferee agrees in writing to be bound
by the terms of this Agreement (a “Permitted Transfer”). Any attempted Transfer of Covered Shares or any interest
therein in violation of this Section 3(a) shall be null and void ab initio.

 

    	3

    	 

    

 

(b)
Non-Solicitation. Prior to the Expiration Date, Stockholder hereby agrees that Stockholder shall not, and shall use its reasonable
best efforts to cause its controlled Affiliates and Representatives not to, directly or indirectly:

 

(i)
solicit, initiate, induce, encourage or facilitate, any inquiries or the making of any proposal or offer that constitutes, or could reasonably
be expected to lead to, a Company Acquisition Proposal;

 

(ii)
participate in any discussions or negotiations or cooperate in any way with any Person regarding any proposal or offer the consummation
of which would constitute a Company Acquisition Proposal;

 

(iii)
provide any non-public information or data concerning the Company or any of its Subsidiaries to any Person in connection with any proposal
the consummation of which would constitute a Company Acquisition Proposal or for the purpose of soliciting, initiating, inducing, encouraging
or facilitating a Company Acquisition Proposal;

 

(iv)
enter into any binding or nonbinding letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement,
agreement in principle, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement
with respect to a Company Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to a Company Acquisition
Proposal;

 

(v)
adopt, approve or recommend or make any public statement approving or recommending any inquiry, proposal or offer that constitutes, or
could reasonably be expected to lead to, a Company Acquisition Proposal (including by approving any transaction, or approving any Person
becoming an “interested stockholder,” for purposes of Section 203 of the DGCL); take any action or exempt any Person (other
than Parent and its Subsidiaries) from the restriction on “business combinations” or any similar provision contained in applicable
takeover laws or the Company’s organizational or other governing documents;

 

(vi)
take any action that could reasonably be expected to lead to a Company Acquisition Proposal except as expressly permitted by Section
5.2 of the Merger Agreement; or

 

(vii)
resolve, publicly propose or agree to do any of the foregoing.

 

(c)
Notification. Prior to the Company Stockholder Meeting, Stockholder shall promptly (and, in any event, within 24 hours) notify
Parent (orally and in writing) if (i) any written or other inquiries, proposals or offers with respect to a Company Acquisition Proposal
or any inquiries, proposals, offers or requests for information relating to or that could reasonably be expected to lead to a Company
Acquisition Proposal are received by Stockholder, (ii) any non-public information is requested in connection with any Company Acquisition
Proposal from the Company or (iii) any discussions or negotiation with respect to or that could reasonably be expected to lead to a Company
Acquisition Proposal are sought to be initiated or continued with the Company, indicating, in connection with such notice, the name of
such Person and the material terms and conditions of any proposals or offers (including, if applicable, copies of any written requests,
proposals or offers, including proposed agreements and other material written communications or, if oral, a summary of the material terms
and conditions of such proposal or offer), and thereafter shall keep Parent informed, on a current basis (and in any event within 24
hours), of the status and terms of any such proposals or offers (including any amendments thereto) and the status of any such discussions
or negotiations, including by promptly providing copies of any additional requests, proposals or offers, including any drafts of proposed
agreements and any amendments thereto and other information set forth above. Promptly following the execution and delivery of this Agreement,
Stockholder shall and shall use its reasonable best efforts to cause its Representatives to, immediately cease and cause to be terminated
any existing solicitation of, or discussions or negotiations with, any Person (other than Parent and its Representatives) relating to
any Company Acquisition Proposal made prior to the date hereof and any access any such Persons may have to any physical or electronic
data room or any confidential or proprietary information relating to any potential Company Acquisition Proposal.

 

    	4

    	 

    

 

4.
Additional Agreements.

 

(a)
Certain Events. In the event of any stock split, stock dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Covered Shares or the acquisition of Additional Owned Shares or other securities or rights
of the Company by Stockholder, (i) the type and number of Covered Shares shall be adjusted appropriately, and (ii) this Agreement and
the obligations hereunder shall automatically attach to any Additional Owned Shares or other securities or rights of the Company issued
to or acquired by Stockholder. In the event of a Company Change in Recommendation, to the extent the Covered Shares (together will all
shares of Company Common Stock subject to voting agreements entered into on the date hereof by and between Company stockholders and Parent)
exceed 30% of the Company Outstanding Shares, then the number of shares of Company Common Stock subject to such voting agreements shall
only be 30% of the Company Outstanding Shares in the aggregate, and the number of shares of Company Common Stock of each such Company
stockholder subject to each such voting agreement shall be reduced proportionately based upon the number of shares of Company Common
Stock subject thereto.

 

(b)
Stop Transfer. In furtherance of this Agreement, Stockholder hereby authorizes and instructs the Company (including through the
Company’s transfer agent) to enter a stop transfer order with respect to all of the Covered Shares, including authorizing the Company
to, as promptly as practicable after the date of this Agreement, make a notation on its records and give instructions to the transfer
agent for the Covered Shares not to permit, during the term of this Agreement, the Transfer of the Covered Shares unless such Transfer
is a Permitted Transfer, provided that promptly following the earlier of (x) the Expiration Date and (y) obtaining the Company
Stockholder Approval, any such stop transfer instructions imposed pursuant to this Section 4(b) shall be lifted.

 

(c)
Waiver of Appraisal and Dissenters’ Rights and Actions. Stockholder hereby (i) waives and agrees not to exercise any rights
of appraisal or rights to dissent from the Merger that Stockholder may have and (ii) agrees not to commence or participate in, assist
or knowingly encourage, and to take all actions necessary to opt out of, any class in any class action with respect to, any action or
claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective Subsidiaries or Affiliates and each
of their successors and assigns relating to the negotiation, execution or delivery of this Agreement or the Merger Agreement or the consummation
of the Merger, including any claim (A) challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement
(including any claim seeking to enjoin or delay the closing of the Merger) or (B) alleging a breach of any fiduciary duty of the Company
Board in connection with the Merger Agreement or the transactions contemplated thereby; provided that nothing in this Section
4(c) shall restrict or prohibit Stockholder from asserting (x) its right to receive the Merger Consideration in accordance with the Merger
Agreement and the DGCL or (y) counterclaims or defenses in any proceeding brought or claims asserted against it by Parent, Merger Sub,
the Company or any of their respective Subsidiaries or Affiliates and each of their successors and assigns relating to this Agreement
or the Merger Agreement, or from enforcing its rights under this Agreement.

 

    	5

    	 

    

 

(d)
Communications. Stockholder shall not, and shall use reasonable best efforts to cause its Representatives not to, make any press
release, public announcement or other communication with respect to the business or affairs of any of the Company, Parent or Merger Sub,
including this Agreement and the Merger Agreement and the transactions contemplated hereby and thereby, without the prior written consent
of Parent. Stockholder hereby (i) consents to and authorizes the publication and disclosure by Parent of Stockholder’s identity
and holding of Covered Shares, and the nature of Stockholder’s commitments, arrangements and understandings under this Agreement
in any press release or any other disclosure document in connection with the Merger or any other transactions contemplated by the Merger
Agreement and (ii) agrees as promptly as practicable to notify Parent of any required corrections with respect to any written information
supplied by Stockholder specifically for use in any such disclosure document.

 

(e)
Additional Owned Shares. Stockholder hereby agrees to notify Parent promptly in writing of the number and description of any Additional
Owned Shares.

 

5.
Representations and Warranties of Stockholder. Stockholder hereby represents and warrants to Parent as follows:

 

(a)
Title. Stockholder is the sole record and beneficial owner of the Covered Shares. The Owned Shares constitute all of the capital
stock and any other equity securities of the Company owned of record or beneficially by Stockholder on the date hereof, and Stockholder
is not the beneficial owner of, and does not have any right to acquire (whether currently, upon lapse of time, following the satisfaction
of any conditions, upon the occurrence of any event or any combination of the foregoing) any shares of Company Common Stock or any other
equity securities of the Company or any securities convertible into or exchangeable or exercisable for shares of Company Common Stock
or such other equity securities, in each case other than the Owned Shares and any Additional Owned Shares. Dr. David Sidranksy, Chairman
of the Board of Directors of the Company and managing partner of Stockholder, is not the beneficial owner of, and does not have any right
to acquire (whether currently, upon lapse of time, following the satisfaction of any conditions, upon the occurrence of any event or
any combination of the foregoing), directly or indirectly, (i) 5% or greater shares of Company Common Stock or any other equity securities
of the Company or any securities convertible into or exchangeable or exercisable for shares of Company Common Stock or such other equity
securities, or (ii) 5% or more of the Merger Consideration. Stockholder (or its nominee or custodian for the benefit of Stockholder)
has sole voting power, sole power of disposition and sole power to issue instructions with respect to the matters set forth in Sections
3 and 4 hereof and all other matters set forth in this Agreement, in each case with respect to all of the Covered Shares with no limitations,
qualifications or restrictions on such rights, subject to applicable securities laws and the terms of this Agreement. Except as permitted
by this Agreement, the Owned Shares and the certificates representing such Owned Shares, if any, are now, and at all times prior to the
Expiration Date will be, held by Stockholder, or by a nominee or custodian for the benefit of Stockholder, free and clear of any and
all liens, pledges, claims, options, proxies, voting trusts or agreements, security interests, understandings or arrangements or any
other encumbrances whatsoever on title, transfer or exercise of any rights of a stockholder in respect of the Owned Shares (other than
as created by this Agreement) (collectively, “Liens”).

 

    	6

    	 

    

 

(b)
Organization and Qualification. If Stockholder is not an individual, Stockholder is a legal entity duly organized, validly existing
and, to the extent such concept is applicable, in good standing under the laws of the jurisdiction of its organization.

 

(c)
Authority. Stockholder has all necessary individual or entity power and authority and legal capacity to, and has taken all action
necessary in order to, execute, deliver and perform all of Stockholder’s obligations under this Agreement, and consummate the transactions
contemplated hereby, and no other proceedings or actions on the part of Stockholder are necessary to authorize the execution, delivery
or performance of this Agreement or the consummation of the transactions contemplated hereby.

 

(d)
Due Execution and Delivery. This Agreement has been duly and validly executed and delivered by Stockholder and, assuming due authorization,
execution and delivery hereof by Parent, constitutes a legal, valid and binding agreement of Stockholder, enforceable against Stockholder
in accordance with its terms, subject to the Bankruptcy and Equity Exception. If Stockholder is an individual and is married, and any
of the Covered Shares constitute community property or spousal approval is otherwise necessary for this Agreement to be legal, binding
and enforceable, this Agreement has been duly authorized, executed and delivered by, and constitutes the legal, valid and binding obligation
of, Stockholder’s spouse, enforceable against Stockholder’s spouse in accordance with its terms.

 

(e)
No Filings; No Conflict or Default. Except for any required filings under the any competition, antitrust and investment laws or
regulations of foreign jurisdictions and the Exchange Act, no filing with, and no permit, authorization, consent or approval of, any
Governmental Entity or any other Person is necessary for the execution and delivery of this Agreement by Stockholder, the consummation
by Stockholder of the transactions contemplated hereby and the compliance by Stockholder with the provisions hereof. None of the execution
and delivery of this Agreement by Stockholder, the consummation by Stockholder of the transactions contemplated hereby or compliance
by Stockholder with any of the provisions hereof will (i) result in a violation or breach of, or constitute (with or without notice or
lapse of time or both) a default (or give rise to any third party right of termination, cancellation, modification or acceleration) under,
any of the terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license, permit, contract, commitment, arrangement,
understanding, agreement or other instrument or obligation of any kind, including any voting agreement, proxy arrangement, pledge agreement,
shareholders agreement or voting trust, to which Stockholder is a party or by which Stockholder or any of Stockholder’s properties
or assets may be bound, (ii) violate any judgment, order, writ, injunction, decree or award of any court, administrative agency or other
Governmental Entity that is applicable to Stockholder or any of Stockholder’s properties or assets, (iii) constitute a violation
by Stockholder of any law or regulation of any jurisdiction, (iv) render Section 203 of the DGCL, or any other state takeover statute
or similar statute or regulation, applicable to the Merger or any other transaction involving Parent, or (v) if Stockholder is not an
individual, contravene or conflict with Stockholder’s governing or organizational documents, in each case, except, in the case
of clauses (i) through (iv), for any conflict, breach, default or violation described above which would not materially impair the ability
of Stockholder to perform its obligations hereunder or consummate the transactions contemplated hereby.

 

    	7

    	 

    

 

(f)
No Litigation. There is no suit, claim, action, investigation or proceeding pending or, to the knowledge of Stockholder, threatened
against Stockholder at law or in equity before or by any Governmental Entity that questions the beneficial or record ownership of Stockholder’s
Covered Shares, the validity of this Agreement or the performance by Stockholder of its obligations under this Agreement or that would
reasonably be expected to materially impair the ability of Stockholder to perform its obligations hereunder or to consummate the transactions
contemplated hereby.

 

(g)
No Fees. No broker, finder or investment banker is entitled to any brokerage, finder’s or other similar fee or commission
in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of Stockholder.

 

(h)
Receipt; Reliance. Stockholder has received and reviewed a copy of the Merger Agreement. Stockholder understands and acknowledges
that Parent and Merger Sub are entering into the Merger Agreement in reliance upon Stockholder’s execution, delivery and performance
of this Agreement and the representations, warranties, covenants and other agreements of Stockholder contained herein.

 

6.
Termination. This Agreement and all rights and obligations of the parties hereunder shall commence on the date hereof and shall
terminate upon the earliest of (such time, the “Expiration Date”) (a) the mutual agreement of Parent and Stockholder,
(b) the Company Stockholders Meeting at which a vote upon the adoption of the Merger Agreement and the approval of the Merger and the
other transactions contemplated by the Merger Agreement is taken and (c) the termination of the Merger Agreement in accordance with its
terms; provided that (i) nothing herein shall relieve any party hereto from liability for any breach of this Agreement and (ii)
this Section 6 and Section 8 shall survive any termination of this Agreement.

 

7.
No Limitation. Nothing in this Agreement shall be construed to prohibit Stockholder or any of Stockholder’s Representatives
who is an officer or member of the Company Board from taking any action (or failing to take any action) solely in his or her capacity
as an officer or member of the Company Board (or any committee thereof) or from taking any action with respect to any Company Acquisition
Proposal as an officer or member of the Company Board (or any committee thereof).

 

8.
Miscellaneous.

 

(a)
Entire Agreement. This Agreement (together with Schedule I) constitutes the entire agreement and supersedes all prior and
contemporaneous agreements and understandings, both written and oral, among or between any of the parties hereto with respect to the
subject matter hereof.

 

    	8

    	 

    

 

(b)
Reasonable Efforts. At the other party’s reasonable request and without further consideration, each party hereto shall execute
and deliver such additional documents and take all such further lawful action as may be reasonably required or necessary to consummate
and make effective, in the most expeditious manner practicable, the transactions contemplated hereby. Without limiting the foregoing,
Stockholder shall execute and deliver to Parent and any of its designees any proxies, including with respect to Additional Owned Shares,
reasonably requested by Parent in furtherance of this Agreement.

 

(c)
No Assignment. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties
hereto and their respective successors and permitted assigns; provided, however, that, except in connection with a Permitted Transfer,
neither this Agreement nor any of a party’s rights or obligations hereunder may be assigned or delegated by such party without
the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations
by such party without the other party’s prior written consent shall be void and of no effect.

 

(d)
Binding Successors. Without limiting any other rights Parent may have hereunder in respect of any Transfer of the Covered Shares,
Stockholder agrees that this Agreement and the obligations hereunder shall attach to the Covered Shares beneficially owned by Stockholder
and shall be binding upon any Person to which legal or beneficial ownership of such Covered Shares shall pass, whether by operation of
law or otherwise, including, without limitation, Stockholder’s heirs, guardians, administrators, Representatives, successors or
permitted assigns.

 

(e)
Amendments. This Agreement may be amended at any time prior to the Effective Time (whether before or after receipt of the Company
Stockholder Approval) by an instrument in writing signed on behalf of each of the parties hereto.

 

(f)
Notice. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and
received hereunder (a) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international
overnight courier service, (b) upon delivery in the case of delivery by hand, or (c) on the date delivered in the place of delivery if
sent by email (if no automated notice of delivery failure is received by the sender) prior to 5:00 p.m. New York time, otherwise on the
next succeeding Business Day, in each case to the intended recipient as set forth below:

 

if
to Parent or Merger Sub

 

Advaxis,
Inc.

212
Carnegie Center, Suite 206

Princeton,
New Jersey 08540

Attention:
Kenneth A. Berlin and Igor Gitelman

Email:
berlin@advaxis.com; gitelman@advaxis.com

 

    	9

    	 

    

 

with
copies to (which shall not constitute notice):

 

Morgan,
Lewis & Bockius LLP

101
Park Avenue

New
York, NY 10178

Attention:
Robert W. Dickey

Email:
robert.dickey@morganlewis.com

 

if
to the Stockholder

 

Israel
Biotech Fund I, L.P.

75
Fort Street, Clifton House

PO
Box, 1350

KYI-1108,
Grand Cayman

Attention:
Sarit Steinberg

Email:
sarit@ibf.fund

 

with
copies to (which shall not constitute notice):

 

Latham
& Watkins LLP

200
Clarendon Street

Boston,
MA 02116

Attention:
Peter N. Handrinos; Joshua M. Dubofsky

Email:
Peter.Handrinos@lw.com; Josh.Dubofsky@lw.com

 

(g)
Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall
not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending
term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares
that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall
have the power to limit the term or provision, to delete specific words or phrases or to replace any invalid or unenforceable term or
provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the
power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a
valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such
invalid or unenforceable term.

 

(h)
Remedies. All rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or in
equity shall be cumulative and not alternative, and the exercise of any such right, power or remedy by any party hereto shall not preclude
the simultaneous or later exercise of any other such right, power or remedy by such party.

 

    	10

    	 

    

 

(i)
No Waiver. Except as otherwise provided in this Agreement, any failure of any of the parties to comply with any obligation, covenant,
agreement or condition herein may be waived by the party or parties entitled to the benefits thereof only by a written instrument signed
by the party granting such waiver. Any such waiver shall not be applicable or have any effect except in the specific instance in which
it is given. No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no delay
on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such
power, right, privilege or remedy. No single or partial exercise of any such power, right, privilege or remedy shall preclude any other
or further exercise thereof or of any other power, right, privilege or remedy.

 

(j)
No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing
in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under
or by reason of this Agreement.

 

(k)
Applicable Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of
Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding
between any of the parties hereto arising out of or relating to this Agreement, each of the parties hereto: (a) irrevocably and unconditionally
consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such
court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that
neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b) agrees that all claims in respect
of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this Section 8(k); (c)
waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an
inconvenient forum or do not have jurisdiction over any party hereto; and (e) agrees that service of process upon such party in any such
action or proceeding shall be effective if notice is given in accordance with Section 8(f) of this Agreement. EACH PARTY HERETO
ACKNOWLEDGES AND AGREES THAT ANY ACTION OR PROCEEDING WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION
OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH,
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY
OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION OR PROCEEDING,
SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (II) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (III) IT MAKES SUCH
WAIVERS VOLUNTARILY AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION 8(k).

 

    	11

    	 

    

 

(l)
Specific Performance. Each of the parties hereto acknowledges and agrees that irreparable damage would occur and that the parties
hereto would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance
with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor.
It is accordingly agreed that, in addition to any other remedy that a party hereto may have under law or in equity, in the event of any
breach or threatened breach by Parent or Stockholder of any covenant or obligation of such party contained in this Agreement, the other
party shall be entitled to obtain an injunction or injunctions, specific performance and other equitable relief to prevent breaches of
this Agreement and to enforce specifically the performance of the terms and provisions hereof, without proof of actual damages (and each
party hereto hereby waives any requirement for the security or posting of any bond in connection with such remedy). The parties hereto
further agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to applicable Law or inequitable
for any reason, and not to assert that a remedy of monetary damages would provide an adequate remedy for any such breach or that Stockholder
or Parent otherwise have an adequate remedy at law. The parties hereto acknowledge that the agreements contained in this Section 8(l)
are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, the parties hereto would
not enter into this Agreement.

 

(m)
Interpretation. The terms of Section 8.11 of the Merger Agreement apply to this Agreement mutatis mutandis.

 

(n)
Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which
shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties
hereto by electronic transmission in .PDF format shall be sufficient to bind the parties hereto to the terms and conditions of this Agreement.

 

(o)
Expenses. Except as otherwise provided herein, each party hereto shall pay such party’s own expenses incurred in connection
with this Agreement.

 

(p)
No Ownership Interest. Nothing contained in this Agreement shall be deemed, upon execution, to vest in Parent any direct or indirect
ownership or incidence of ownership of or with respect to any Covered Shares. All rights, ownership and economic benefits of and relating
to the Covered Shares shall remain vested in and belong to Stockholder, and Parent shall have no authority to manage, direct, superintend,
restrict, regulate, govern or administer any of the policies or operations of the Company or exercise any power or authority to direct
Stockholder in the voting of any of the Covered Shares, except as otherwise provided herein.

 

(q)
Capacity as Stockholder. Notwithstanding anything herein to the contrary, Stockholder signs this Agreement solely in Stockholder’s
capacity as a stockholder of the Company, and not in any other capacity, and this Agreement shall not limit or otherwise affect the actions
(or failure to take any actions) of any Affiliate, employee or designee of Stockholder or any of its Affiliates in his or her capacity,
if applicable, as an officer or director of the Company or any other Person.

 

[Signature
page follows]

 

    	12

    	 

    

 

IN
WITNESS WHEREOF, Parent and Stockholder have caused this Agreement to be duly executed as of the date first written above.

 

	 	ADVAXIS,
    INC.
	 	 	 
	 	By:	 /s/
                                            Kenneth A. Berlin 

	 	Name:	 Kenneth A. Berlin 
	 	Title:	 President and Chief Executive Officer 
	 	 	 
	 	ISRAEL
    BIOTECH FUND I, L.P.
	 	By
    its general partner:
	 	Israel
    Biotech Fund GP Partners, L.P.
	 	By
    its general partner: 
	 	I.B.F.
    Management, Ltd.
	 	 	 
	 	By:	 /s/
    Yuval Cabilly 
	 	Name:
    	 Yuval Cabilly 
	 	Title:
    	 CEO 

 

[Signature Page to Voting and Support Agreement]

 

    	 

    	 

    

 

SCHEDULE I

 

	Name
    and Contact Information for Stockholder	 	Number
    of Shares of Company Common Stock Beneficially Owned
	Israel
    Biotech Fund I, L.P.

    75
    Fort Street, Clifton House

    PO
    Box, 1350

    KYI-1108,
    Grand Cayman
	 	3,315,119

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]